In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.